Onset and enhancement of systemic sclerosis after treatments for multiple sclerosis

Rheumatology International

Volumn 28, Issue 7, 2008, Pages 703-707

  Airo', Paolo ^a   Scarsi, Mirko ^a   Rossi, Mara ^b   Mondini, Michele ^c,d  

^a Rheumatology and Clinical Immunology   (Italy)

^b Spedali Civili   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Corticosteroids; Interferon; Multiple sclerosis; Renal crisis; Systemic sclerosis

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; BETA INTERFERON; CORTICOSTEROID; DOBUTAMINE; ILOPROST; IRBESARTAN; METHYLPREDNISOLONE; RAMIPRIL;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CLINICAL EXAMINATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DOSE RESPONSE; DRUG MEGADOSE; ECHOCARDIOGRAPHY; HUMAN; HYPERTENSION; KIDNEY FAILURE; LABORATORY TEST; LOW DRUG DOSE; LUNG FUNCTION TEST; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RELAPSE; SCLERODERMA; SYSTEMIC SCLEROSIS; ULCER;

HUMANS; INTERFERON TYPE I; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC;

EID: 41849105428     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-007-0507-2     Document Type: Article

References (25)

1. Sakkas LI, Xu B, Artlett CA, Lu S, Jimenez SA, Platsoucas CD (2002) Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 168:3649-3659
2. Trostle DC, Helfrich D, Medsger TA Jr (1986) Systemic sclerosis (scleroderma) and multiple sclerosis. Arthritis Rheum 29:124-127
3. Igarashi A, Imakado S, Ishibashi Y, Takehara K (1989) Systemic sclerosis associated with multiple sclerosis. Arch Dermatol 125:1145
4. Jawad SH, Askari A, Ward AB (1997) Case history of a patient with multiple sclerosis and scleroderma. Br J Rheumatol 36:502-503
5. Spadaro A, Sensi F, Barrella M, Francia A (1999) Systemic sclerosis and multiple sclerosis. J Neurol 246:497-499
6. Chroni E, Paschalis C, Stergiou T, Vlahanastasi C, Andonopoulos AP (2002) Multiple sclerosis in the course of systemic sclerosis. Ann Rheum Dis 61:188-190
7. Gorodkin R, Leahy B, Neary D, Herrick AL (2004) Coexistence of systemic sclerosis and multiple sclerosis. J Neurol 251:1524-1525
8. Pelidou SH, Tsifetaki N, Giannopoulos S, Deretzi G, Voulgari P, Kyritsis A (2007) Multiple sclerosis associated with systemic sclerosis. Rheumatol Int 27:771-773
9. Do HT, Baars W, Borns K, Windhagen A, Schwinzer R (2006) The 77C > G mutation in the human CD45 (PTPRC) gene leads to increased intensity of TCR signalling in T cell. J Immunol 176:931-938
10. Schwinzer R, Witte T, Hundrieser J, Ehlers S, Momot T, Hunzelmann N, Krieg T, Schmidt RE, Wonigeit K (2003) Enhanced frequency of a PTPRC (CD45) exon A mutation (77C- > G) in systemic sclerosis. Genes Immun 4:168-169
11. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227-231
12. Mondini M, Vidali M, De Andrea M, Azzimonti B, Airo' P, D'ambrosio R, Riboldi P, Meroni PL, Albano E, Schoenfeld Y, Gariglio M, Landolfo S (2006) A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16. Arthritis Rheum 54:3939-3944
13. Airo' P, Rossi M, Scarsi M, Danieli E, Grottolo A, Zambruni A (2007) Disease-modifying effects of long-term cyclic iloprost therapy in systemic sclerosis. A retrospective analysis and comparison with a control group. Clin Exp Rheumatol (in press)
14. Theodoridou A, Settas L (2006) Demyelination in rheumatic diseases. J Neurol Neurosurg Psychiatry 77:290-295
15. DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL, Mayes M, White B, Wigley F, Barr W, Moreland L, Medsger TA Jr, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Clements PJ (2002) Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 46:2983-2989
16. Steen VD (2005) Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35:35-42
17. Linden D (1998) Severe Raynaud's phenomenon associated with interferon-beta treatment for multiple sclerosis. Lancet 352:878-879
18. DeBroucker T, Lhote F (2000) Severe Raynaud's phenomenon associated with interferon-beta 1a and fluoxetine. Ann Med Interne (Paris) 15:424-425
19. Cruz BA, De Queiroz E, Vilela Nunes S, Cruz Filho A, Campos GB, Lentz deCarvalho Monteiro E, Crivellari H (2000) Fênomeno de Raynaud grave associado a terapia com interferon-beta para esclerose múltipla. Arq Neuropsiquiatr 58:556-559
20. Schapira D, Nahir AM, Hadad N (2002) Interferon-induced Raynaud's syndrome. Semin Arthritis Rheum 32:57-62
21. Beretta L, Caronni M, Vanoli M, Scorza R (2002) Systemic sclerosis after interferon alfa therapy for myeloproliferative disorders. Br J Dermatol 147:385-386
22. Solans R, Bosch JA, Esteban I, Vilardell M (2004) Systemic sclerosis developing in association with the use of interferon alpha therapy for chronic viral hepatitis. Clin Exp Rheumatol 22:625-628
23. Tahara H, Kojima A, Hirokawa T, Oyama T, Naganuma A, Maruta S, Okada K, Ban S, Yoshida K, Takagi H, Mori M (2007) Systemic sclerosis after interferon alphacon-1 therapy for Hepatitis C. Intern Med 46:473-476
24. Black CM, Silman AJ, Herrick AI, Denton CP, Wilson H, Newman J, Pompon L, Shi-Wen X (1999) Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arhritis Rheum 42:299-305
25. Tan FK, Zhou X, Mayes MD, Gourh P, Guo X, Marcum C, Jin L, Arnett FC Jr (2006) Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology 45:694-702